Tonix Pharmaceuticals stock halted ahead of FDA approval news
BioCardia, Inc. (NASDAQ:BCDA) President and CEO Peter Altman reported purchasing 400 shares of common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The purchase comes as the company’s stock trades near its 52-week low of $1.62, having declined over 30% in the past year. According to InvestingPro analysis, the company’s financial health score is currently rated as WEAK, with a market capitalization of approximately $9.75 million.
The shares were bought at a weighted average price of $1.751, for a total transaction value of $700. The prices for individual purchases ranged from $1.70 to $1.83. Following the transaction, Altman directly owns 167,962 shares of BioCardia. InvestingPro analysis reveals 12 additional key insights about BioCardia’s financial position and market performance, available exclusively to subscribers through the comprehensive Pro Research Report.
In other recent news, BioCardia Inc. reported its second-quarter 2025 earnings, revealing a net loss of $2 million, compared to a $1.6 million loss in the same period last year. The company noted that the increased expenses were largely due to heightened research and development activities. Despite the financial loss, BioCardia highlighted significant progress in its clinical trials and regulatory efforts. These developments suggest a strategic focus on advancing their pipeline, even as costs rise. While the stock experienced some decline, the company’s emphasis remains on long-term growth through innovation. Investors may be interested in how these advancements could impact future financials. The results also underscore the challenges and opportunities in balancing R&D investments with financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.